glp-1 cv outcome trials receptor agonists were developed for glycemic control. The cardiovascular data has since reframed how cardiologists need to think about this drug class entirely. Across LEADER, SUSTAIN-6, REWIND, and SELECT, GLP-1 Results of cardiovascular outcomes trials

This dramatic rise reflects updated clinical guidelines from the American Diabetes Association (ADA), which now recommend GLP-1 receptor agonists as first-line therapy for many patients

What else you should know Victoza and Saxenda are the same medication: liraglutide

What does Tirzepatide do for weight loss

[17] [18] As a precaution, individuals with a personal or family history of medullary thyroid carcinoma or MEN2 are typically excluded from trials

11,107 Intracerebroventricular injection of GLP-1 induces satiety in rats, and this is reversed by exendin 939 demonstrating that GLP-1 mediates its actions via its receptor here

However, whether Semaglutides effect is mitigating or exacerbating remains unclear, emphasizing the necessity for further research on the outcome of GLP-1R agonists on cancer, specifically thyroid cancer